Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …

Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …

Background Responses to conventional donor lymphocyte infusion for postallogeneic
hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell …

In spite of the remarkable progress in basic and preclinical studies of acute myeloid
leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …

Background Immune exhaustion and senescence are dominant dysfunctional states of
effector T cells and major hurdles for the success of cancer immunotherapy. In the current …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion
of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in …

Abstract Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term
survival outcomes, are mostly effective in patients with immune-responsive tumors. Most …